Abstract. Proteasome inhibitors represent a novel class of drugs that have clinical efficacy against hematological and solid cancer types, including acute myeloid leukaemia, myelodysplastic syndrome an non-small cell lung cancer. It has been demonstrated that the anti-apoptotic protein B-cell lymphoma-2-associated athanogene 3 (BAG3) is induced by proteasome inhibitors in various cancer cells and serves an important role in chemotherapy resistance. The phosphatidylinositol 3-kinase (PI3K)/RAC-α serine/threonine-protein kinase (AKT) pathway is constitutively activated in a number of lymphoid malignancy types, including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. In the present study, the aim was to elucidate the role of the PI3K/AKT signaling pathway in the induction of BAG3, following exposure to a proteasome inhibitor in DLBCL cell lines. Bortezomib and MG132 were used as proteasome inhibitors. Western blotting was used to evaluate the roles of proteasome inhibitors and the PI3K/AKT pathway in BAG3 induction in DLBCL cells (LY1 and LY8), and LY294002 was used to block the PI3K/AKT pathway. Cell viability was detected using a Cell Counting Kit-8 assay. Apoptosis of LY1 and LY8 cells was quantified by Annexin V/7-amino-actinomycin D flow cytometry. The BAG3 protein was markedly induced upon exposure to bortezomib and MG132 in a dose-dependent manner. The PI3K/AKT inhibitor LY294002 significantly suppressed the induction of BAG3 by proteasome inhibitors. Inhibition of the PI3K/AKT pathway decreased the proliferation and increased the apoptosis induced by proteasome inhibitors. The present results indicated that the PI3K/AKT pathway is associated with the activation of BAG3 expression in DLBCL cells, and is involved in the protective response against proteasome
Introduction
Diffuse large B-cell lymphoma (DLBCL) is considered to be the most common subtype of non-Hodgkin lymphoma globally (1) . In adults, DLBCL accountedfor 30-40% of all cases of non-Hodgkin lymphoma worldwide until 2014 (2) . Although significant advances have been made during the last few years in the treatment of DLBCL, particularly with immunochemotherapy, approximately one third of cases remain fatal according to a recent research in the United States in 2016, frequently due to chemotherapy resistance (3, 4) . Therefore, continued investigations into novel therapeutic strategies are required.
Bortezomib is a proteasome inhibitor, a novel class of drugs that have antitumor activity, primarily through inhibition of the nuclear factor (NF)-κB pathway. Additionally, it has been approved clinically for treatment of multiple myeloma and mantle cell lymphoma (5) . Furthermore, a number of clinical trials have demonstrated that bortezomib has promising activity in patients with relapsed/refractory DLBCL (6) (7) (8) . However, it may induce the expression of certain anti-apoptotic proteins, including heat shock protein 90 (9) and the antiapoptic Bcl-2 family member Mcl-1 (10) , that could limit its antitumor efficacy. It has been demonstrated that B-cell lymphoma-2-associated athanogene 3 (BAG3), an anti-apoptotic molecule, is induced by proteasome inhibitors in various cancer cells, and BAG3 knockdown by small interfering RNA sensitizes cancer cells to proteasome inhibitor-induced apoptosis (11) .
BAG3, also known as CAIR-1 or Bis, is a member of the BAG protein family. It contains a conserved domain and binds the ATPase domain of heat shock protein 70 (12) . BAG3 mediates protein delivery to the proteasome, modulates apoptosis and serves a role in the processes of cell adhesion and migration (13) . Evidence has indicated that BAG3 expression is upregulated in a number of cancer cell lines (14) (15) (16) (17) (18) (19) (20) , including thyroid carcinoma, pancreatic cancer, prostate cancer, leukemic cells, ovarian cancer, neuroblastoma and glioblastoma. As reported, BAG3 acts as a pro-survival and anti-apoptotic protein in different cancer cells, and it underlies resistance to chemotherapy through decreasing the level of apoptosis (14, 15, 18) . Additionally, inhibition of BAG3 expression could potentiate the effectiveness of chemotherapy (21) , indicating that BAG3 is a candidate therapeutic target of human cancer. The phosphatidylinositol 3-kinase (PI3K)/RAC-α serine/threonine-protein kinase (AKT) pathway is constitutively activated in a number of lymphoid malignancy types, primarily by phosphorylation (22, 23) . It has been implicated as serving crucial roles in the activation of growth and anti-apoptotic pathways (24) . Overexpression of phosphorylated (p)-AKT is associated with a poor outcome in DLBCL (22, 25) . Thus, the PI3K/AKT signaling pathway may represent a promising target for therapeutic intervention in DLBCL.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3
A number of studies reported that BAG3 may be induced by proteasome inhibitors, but this has not been investigated in DLBCL cell lines (26) (27) (28) . It has been demonstrated that the anticancer effect of bortezomib is enhanced by PI3K/AKT pathway inhibitors in a number of tumor types, including myelodysplastic syndrome (29) , hepatocellular carcinoma (30) and melanoma (31) , however, this also has not been investigated in DLBCL. The present study therefore aimed to investigate whether proteasome inhibitors induce BAG3 in DLBCL cell lines, whether there is a synergistic anticancer effect between proteasome inhibitors and PI3K/AKT pathway inhibitors in DLBCL cell lines, and whether the synergy effect was due to the decreased expression of the anti-apoptotic protein BAG3. In the present study, it was demonstrated that the PI3K/AKT inhibitor LY294002 significantly suppressed the induction of BAG3 by proteasome inhibitors in DLBCL cell lines. It was further observed that inhibition of the PI3K/AKT pathway decreased the level of proliferation and increased the level of apoptosis induced by proteasome inhibitors. These results indicated that inhibition of the PI3K/AKT pathway could enhance sensitivity of DLBCL cells to proteasome inhibitors, at least partially, by suppression of BAG3 expression. To analyze the effects of LY294002, MG132 and bortezomib on cell growth and expression of BAG3, LY1 and LY8 cells were cultured in the presence or absence of the drugs for 24 h at 37˚C, the working concentrations of LY294002 were 2.5, 5, 10, 20 and 40 µM, the working concentrations ofbortezomib were 5, 10, 20, 40 and 80 nM, and the working concentrations of MG132 were 0.5, 1, 2, 4 and 8 µM. For experiments with LY294002 and proteasome inhibitor (bortezomib and MG132) treatments, LY1 and LY8 cells were pre-treated with LY294002 for 1 h prior to exposure to proteasome inhibitors.
Materials and methods

Antibodies
Western blotting. Total protein was extracted by radioimmunoprecipitation assay buffer (Shenergy Biocolor Ltd., Shanghai, China), 1% phenylmethylsulfonyl fluoride and 1% phosphatase inhibitor. Protein concentrations were assessed using a Bicinchoninic Acid assay prior to loading the samples. Equal amounts of 40 µg totalprotein was separated via 8% SDS-PAGE and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were blocked at room temperature for 1 h with 5% defatted milk dissolved in tris-buffered saline containing 0.05% Tween-20 (TBST), and then membranes were incubated overnight at 4˚C with primary antibodies against BAG3 (dilution, 1:5,000; cat. no. ab92309; Abcam), AKT1 (dilution, 1:8,000; cat. no. ab32505; Abcam) and pAKT1 (dilution, 1:8,000; cat. no. ab81283; Abcam). Membranes were washed with TBST followed by hybridized at room temperature for 1 h with the anti-rabbit and anti-mouse IgG horseradish peroxidase (HRP)-conjugated secondary antibodies (dilution, 1:1,000; cat. no. SPN-9001 and SPN-9002 respectively; OriGene Technologies, Inc., Beijing, China). Protein bandswere detected using an Enhanced Chemiluminescence Detection kit (EMD Millipore). GAPDH (dilution, 1:1,000; cat. no. TA-08; OriGene Technologies, Inc.) was used as the endogenous control.
Assessment of cell viability. The antiproliferative effects of LY294002 and proteasome inhibitors, alone or in combination, were determined using a Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology, Haimen, China). Briefly, cells (1x10 5 ) were incubated in IMDM for 24 h at 37˚C in a humidified atmosphere containing 5% CO 2 , in triplicate, in a 96-well plate. LY294002 (0, 2.5, 5, 10, 20 and 40 µM), bortezomib (0, 5, 10, 20, 40 and 80 nM) and MG132 (0, 0.5, 1, 2, 4 and 8 µM) were then added to the cultures. After 24 h incubation at 37˚C, 10 µl CCK-8 was added to each well. After 24 h incubation at 37˚C in a humidified atmosphere containing 5% CO 2 , the absorbance at a wavelength of 450 nm was measured. The percentage cell viability was calculated as follows: (A in experimental group -A in blank group/A in control group -A in blank group) x1 00%.
Flow cytometric analysis. LY1 and LY8 cells were treated with LY294002 (10 µM), or together with bortezomib (40 nM) for 24 h at 37˚C, and then cells were harvested and the percentage apoptosis was measured by flow cytometry. Briefly, an aliquot of 1x10 5 Effects of proteasome inhibitors and LY294002 on cell viability. Subsequently, it was determined whether the proteasome inhibitors and PI3K/AKT pathway inhibitor affect the DLBCL cell viability, and whether they have synergistic effects on cell death. The survival rates of LY1 and LY8 cells were measured with a CCK-8 assay. Fig. 2A -C depicts that cell viability was inhibited by bortezomib, MG132 and LY294002 in a concentration-dependent manner. The IC 50 of bortezomib, MG132 and LY294002 in LY1 cells were 45 nM, 4.5 and 12 µM, respectively. In LY8 cells, the IC 50 of bortezomib, MG132 and LY294002 were 42 nM, 4.5 and 13 µM, respectively. Therefore, 40 nM bortezomib, 4 µM MG132 and 10 µM LY294002 were selected as the working concentrations for the following experiments. The PI3K/AKT pathway inhibitor LY294002 significantly decreased cell viability when used in combination with bortezomib and MG132 compared withseparate treatments ( Fig. 2D; P<0 .05), indicating that the PI3K/AKT pathway has a role in the tolerance of DLBCL cells to proteasome inhibitors.
Results
Effects of proteasome inhibitors
Role of PI3K/AKT inhibitor in proteasome inhibitor-induced BAG3 expression.
To investigate whether the PI3K/AKT pathway was involved in the proteasome inhibitor-induced BAG3 expression in DLBCL cell lines, and to confirm whether the decreased cell viability effect of LY294002 with proteasome inhibitors was associated with the expression of the anti-apoptotic protein BAG3, the expression level of BAG3 was detected in LY1 and LY8 cells, which were pre-treated with LY294002 and then co-cultured with proteasome inhibitors for 24 h. The AKT1 and p-AKT1 protein levels were detected by western blot analysis to represent the activation state of the PI3K/AKT pathway. The results of western blot analysis demonstrated that LY294002 notably suppressed the expression of BAG3 induced by proteasome inhibitors (P<0.05). The treatment with the proteasome inhibitors demonstrated no significant effect on relative p-AKT1 protein expression levels, compared with the controls, whereas pre-treatment with LY294002 markedly reduced p-AKT1 protein levels (Fig. 3) . The data indicated that the PI3K/AKT pathway was involved in the induction of BAG3 expression by proteasome inhibitors in DLBCL cell lines.
Bortezomib-induced apoptosis is promoted by LY294002.
Subsequently, it was investigated whether PI3K/AKT inhibitor LY294002 affected the apoptotic response of DLBCL cells to bortezomib by flow cytometric analysis. Cells were incubated with LY294002 (10 µM) for 1 h prior to exposure to bortezomib (40 nM), and then LY1 and LY8 cells were collected after 24 h to detect the apoptotic rate. The results are presented in Fig. 4 . The levels of apoptosis were elevated in LY1 and LY8 cells when treated with LY294002 in combination with bortezomib, compared with the controls and the single treatment groups (P<0.05). In the bortezomib treated group, the apoptotic rates of LY1 and LY8 cells were 4.70±0.36 and 4.00±0.78%, respectively, in the LY294002 treated group, the apoptotic rates of LY1 and LY8 cells were 3.57±2.51 and 3.73±1.20%, respectively, and the percentage of apoptotic cells in bortezomib+LY294002 group reached 7.70±0.56 (LY1) and 7.00±0.49% (LY8). The results indicated the sensitizing effects of LY294002 on the apoptotic responses of DLBCL cells to bortezomib.
Discussion
In the present study, it was observed that proteasome inhibitors activated the expression of BAG3 in DLBCL cells. The present data demonstrated that LY294002, a specific inhibitor of the PI3K/AKT pathway, significantly reduced BAG3 expression induced by proteasome inhibitors in DLBCL cells. The decreased expression of BAG3 was associated with reduced cell viability and increased apoptotic rate. Blockage of the PI3K/AKT pathway not only inhibited BAG3 expression, but also contributed to sensitivity of DLBCL cells to proteasome inhibitors. These data indicated that targeting the PI3K/AKT pathway could overcome resistance of DLBCL cells to proteasome inhibitors, partially through downregulation of BAG3 expression.
Proteasome inhibitors are emerging as a promising class of chemotherapeutic agents in the treatment of a variety of cancer types, including multiple myeloma, mantle cell lymphoma, acute myeloid leukaemia, myelodysplastic symdrome, non-small cell lung cancer and breast cancer (32) (33) (34) (35) (36) . Their anticancer activities are performed through a number of cellular mechanisms, including induction of apoptosis, interference with cell cycle progression and inhibition of angiogenesis (36, 37) . For DLBCL, data demonstrated that proteasome inhibitors, including bortezomib, inhibit constitutive NF-κB activity and result in inhibition of cell proliferation via the induction of apoptosis in the activated DLBCL cells (38) . However, in clinical trials, it has been observed that bortezomib alone has no significant notably increased response and median overall survival in activated B cell-like (ABC) DLBCL, compared with germinal center B cell-like (GCB) DLBCL (39) . The results indicated that a number of unknown mechanisms could induce chemotherapy resistance of GBC DLBCL to proteasome inhibitors. In DLBCL, a synergistic effect of proteasome inhibitors combined with a number of novel agents has been demonstrated, including mechanistic target of rapamycin kinase inhibitors (40) , the Bruton tyrosine kinase inhibitor (41) and the pan-histone deacetylase inhibitor (42) . In multiple tumor models, including glioblastoma and mantle cell lymphoma, the anticancer ability of bortezomib has been demonstrated to be enhanced by combination with PI3K pathway inhibitors (43) (44) (45) (46) . For the first time, the synergy effect of bortezomib in combination with the PI3K/AKT pathway inhibitor LY294002 in DLBCL cells was elucidated.
Accumulating evidence indicated that BAG3, an anti-apoptotic protein, could be induced by proteasome inhibitors and may be responsible for the resistance to chemotherapy in various cell lines (14) (15) (16) (17) (18) (19) (20) . It has been reported that bortezomib upregulates BAG3 expression in leukemic cells and BAG3 gene silencing notably potentiates the apoptosis level of this drug (21) . Downregulation of BAG3 has been observed to increase cell death in response to proteasome inhibition in various cancer cells (21, 27, 28) . Collectively, these reports indicatedthat BAG3 induction is an unwanted molecular consequence of utilizing proteasome inhibitors to combat the malignant diseases, and thus may represent a potential therapeutic target for treating cancer with proteasome inhibitors.
In the present study, the mechanisms of chemoresistance of GCB DLBCL to proteasome inhibitors in the GCB DLBCL cell lines LY1 and LY8 was investigated, with the primary focus on the sensitizing effect of PI3K/AKT pathway inhibitor LY294002 to the proteasome inhibitors, and the association between the synergy effect and the expression level of the anti-apoptotic protein BAG3. Other investigators demonstrated the molecular mechanism of BAG3 upregulation induced by proteasome inhibitors (26) (27) (28) 47) . It has been reported that heat shock transcription factor 1 is involved in BAG3 induction by proteasome inhibitor MG132 (26, 47) . The c-Jun N-terminal kinase pathway has been reported to be associated with the protective response against proteasome inhibition, by mediating induction of BAG3 (28) . In rhabdomyosarcoma cells, NF-κB-inducing kinase (NIK) is critical in mediating NF-κB activation and BAG3 induction upon co-treatment of cytoplasmic HDAC inhibitor and proteasome inhibitor (27) . The present study revealed for the first time that inhibition of the PI3K/AKT signaling pathway enhanced sensitivity of DLBCL cells to proteasome inhibitors by suppression of BAG3 expression.
In the present study, there are various shortcomings. In addition to the conclusions drawn, it was determined that proteasome inhibitors have a tendency to activate the PI3K signaling pathway, but the result was not statistically significant. The results demonstrated that the two inhibitors had a synergistic effect that was statistically significant, but the synergistic effect was not notably pronounced. It is possible that alternative signaling pathways, including those involved in autophagy, may have been activated in response to combined treatment and may explain the observed reduction in cell viability. The exact mechanism by which BAG3 participates in the proteasome inhibitor induced expression and the PI3K signaling pathway requires further investigation.
In conclusion, the present data demonstrated that the PI3K/AKT pathway was associated with the activation of BAG3 expression in DLBCL cells and was involved in the protective response against proteasome inhibition. These results may have notable impact on the development of combined targeted approaches in DLBCL. Targeting BAG3 or the PI3K/AKT pathway combined with bortezomib may have an exciting anticancer effect for patients with GCB DLBCL. Additionally, animal, preclinical and clinical studies are required to validate the present results in future studies.
